The effect of targeted therapy on recruited cancer stem cells in a head and neck carcinoma model

Marcu, Loredana G.; Marcu, David

doi:10.1111/cpr.12380

Cited by 5 publications

(5 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[26,44] ATRA is particularly effective at reversing the CSC phenotype and decreasing the expression of CSC-associated genes in cancer cells that acquire a CSC phenotype during drug resistance. [17,45] In combination with DDP, ATRA can increase tumor sensitivity to DDP, inhibit DDP resistance, and improve the therapeutic efficacy of DDP. [28,46] We tested for CSC-related indicators by western blotting (WB) assays and found that the expression of cluster of differentiation 44 (CD44) was significantly reduced in the DA/Pep1 group (Figure 3O and Figure S32 (Supporting Information)), indicating that the Pep1-loaded drug carrier could reduce the stemness of tumor cells.…”

Section: Effects Of the Peptide Nanocarrier Particles On The Migratio...mentioning

confidence: 99%

pH‐Triggered Transformable Peptide Nanocarriers Extend Drug Retention for Breast Cancer Combination Therapy

Yuan,

Liu,

et al. 2024

Adv Healthcare Materials

View full text Add to dashboard Cite

Increasing the penetration and accumulation of antitumor drugs at the tumor site are crucial in chemotherapy. Smaller drug‐loaded nanoparticles (NPs) typically exhibit increased tumor penetration and more effective permeation through the nuclear membrane, whereas larger drug‐loaded NPs show extended retention at the tumor site. In addition, cancer stem cells (CSCs) have unlimited proliferative potential and are crucial for the onset, progression and metastasis of cancer. Therefore, we designed a drug‐loaded amphiphilic peptide, DA/Pep1, that self‐assembles into spherical NPs upon the encapsulation of cis‐diamminedichloroplatinum (DDP) and all‐trans retinoic acid (ATRA). In an acidic environment, DA/Pep1 transforms into aggregates containing sheet‐like structures, which significantly increases drug accumulation at the tumor site, thereby increasing antitumor effects and inhibiting metastasis. Moreover, although DDP treatment can increase the number of CSCs present, ATRA can induce the differentiation of CSCs in breast cancer to increase the therapeutic effect of DDP. In conclusion, this peptide nanodelivery system that transforms in response to the acidic tumor microenvironment is an extremely promising nanoplatform that suggests a new idea for the combined treatment of tumors.This article is protected by copyright. All rights reserved

show abstract

Section: Effects Of the Peptide Nanocarrier Particles On The Migratio...mentioning

confidence: 99%

pH‐Triggered Transformable Peptide Nanocarriers Extend Drug Retention for Breast Cancer Combination Therapy

Yuan,

Liu,

et al. 2024

Adv Healthcare Materials

View full text Add to dashboard Cite

show abstract

“…(2) Inhibitors have inhibitory effect on blood vessels: tumor has the characteristic of diffusivity, and its main expansion medium is blood vessel [18][19].The main mechanism of the inhibitor is to inhibit tumor angiogenesis, to block the access of tumor cells to nutrient supply, and to regulate the activity of proteolytic enzyme and the expression of vascular endothelial growth factor on tumor cells. And then multiple targets play a good role in anti-tumor angiogenesis [20].Not only can the patient's neovascularization inhibition, but also effectively reduce the number of tumor microvessels.…”

Section: Treatment Of Epidermal Growth Factor Receptor Inhibitormentioning

confidence: 99%

Analysis and Prospect of Targeted Therapy for Head and Neck Tumors

Yizhou¹

2018

TRANC

View full text Add to dashboard Cite

Head and neck tumors account for 30% of malignant tumors in the body, which is a key topic in the world. The comparative data of radiotherapy, surgical therapy or chemotherapy for the treatment of these diseases are given. The treatment of epidermal growth factor receptor inhibitor, cyclin dependent kinase inhibitor and insulin-like growth factor receptor inhibitor were analyzed. It is pointed out that molecular targeted therapy is a targeted blocker to interfere with the signal transduction pathway, which is regulated by the specific molecule and is closely related to the occurrence of tumor, so as to inhibit tumor growth and metastasis.

show abstract

“…2 Tumour-targeted gene therapy may be a complementary treatment for gastric cancer. [4][5][6] The frizzled receptors (FZDs) are characteristic of seven-pass transmembrane proteins, with WNT glycoproteins as their ligands. 3 However, in order to improve the targeting by gene therapy, there is still a long way to go to find cancer-specific genes.…”

Section: Introductionmentioning

confidence: 99%

“…To achieve this goal, a range of tumour-targeting promoters and cytotoxins have been discovered and used in cancer therapy. [4][5][6] The frizzled receptors (FZDs) are characteristic of seven-pass transmembrane proteins, with WNT glycoproteins as their ligands. 7 Tumour formation can result from aberrant activation of FZDs.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Shiga‐like toxin I exerts specific and potent anti‐tumour efficacy against gastric cancer cell proliferation when driven by tumour‐preferential Frizzled‐7 promoter

Peng

Shen

et al. 2019

Cell Proliferation

View full text Add to dashboard Cite

Objectives: Tumour-targeted gene therapy is a promising approach for effective control of gastric cancer cell proliferation. Our study aims to develop a cancer therapy which combines tumour-targeting promoters with cytotoxins. Methods:The expression of globotriaosylceramide (Gb3), which is a Shiga-like toxin I (Stx1) receptor, was verified in gastric cancer compared with normal stomach tissues as assessed by flow cytometry and immunohistochemical analysis. We therefore constructed the recombinant pFZD7-Stx1 plasmid vectors with tumour-preferential Frizzled-7 promoter and Stx1. pFZD7-Stx1 was used to treat gastric cancer in vitro and in vivo. The gastric cancer cell proliferation and tumour growth were identified after the transfection with the pFZD7-Stx1.Results: Globotriaosylceramide was obviously increased in gastric cancer compared with normal stomach. The gastric cancer cell proliferation and tumour growth decreased significantly after the transfection with the pFZD7-Stx1.Conclusion: Frizzled-7 promoter is preferentially active, and Gb3 is abundant in gastric cancer cells. Frizzled-7 promoter and Stx1 may be used to determine a novel and relatively specific and potent gastric cancer therapeutic strategy.Taken together, the Frizzled-7 promoter is preferentially active and Gb3 is abundant in gastric cancer cells. An improved and comprehensive understanding of these and future methods that combine use of the Frizzled-7 promoter and Stx1 will define possibly definitive inhibiting of gastric cancer cell proliferation.

show abstract

The effect of targeted therapy on recruited cancer stem cells in a head and neck carcinoma model

Abstract: The model shows that ATRA exhibits a powerful effect on CSCs when combined with radiotherapy. However, the more radioresistant quiescent cell population should not be ignored, as it can be a potential threat to treatment outcome when cells are recruited into the cell cycle.

Cited by 5 publications

References 27 publications

pH‐Triggered Transformable Peptide Nanocarriers Extend Drug Retention for Breast Cancer Combination Therapy

pH‐Triggered Transformable Peptide Nanocarriers Extend Drug Retention for Breast Cancer Combination Therapy

Analysis and Prospect of Targeted Therapy for Head and Neck Tumors

Shiga‐like toxin I exerts specific and potent anti‐tumour efficacy against gastric cancer cell proliferation when driven by tumour‐preferential Frizzled‐7 promoter

Contact Info

Product

Resources

About